ReviewKidney international reports2021
Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Review in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- The effect of perioperative erythropoietin-stimulating agents and intravenous iron on patient outcomes following solid organ transplantation: A systematic review.Transfusion medicine (Oxford, England) · 2026Pooled it
- Influence of intravenous iron therapy on mortality and cardiovascular events of patients on hemodialysis: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review.Frontiers in nephrology · 2024Pooled it
- Oral liposomal iron vs. oral iron polymaltose in children with chronic kidney disease iron deficiency anemia: a cross-over study.Pediatric nephrology (Berlin, Germany) · 2026Trial
- Liposomal iron dramatic effect on chronic kidney disease pediatric anemia: a randomized clinical trial.Pediatric research · 2026Trial
- Pilot pragmatic clinical trial of iron therapy in children with anemia of chronic kidney disease (FeTCh-CKD).Pediatric nephrology (Berlin, Germany) · 2026Trial
- Comparison of the Effect of Omega-3 vs. MCT Supplementation on Iron-Related Indices in Patients Undergoing Dialysis.Biological trace element research · 2025Trial
- Oral lactoferrin as a treatment of pediatrics' anemia resulted from chronic kidney diseases: a randomized controlled trial.Scientific reports · 2025Trial
- The roles of free-fatty acid receptors in the pathophysiology of renal disorders.The Journal of pharmacology and experimental therapeutics · 2026Review
- The Role of Diet and Gut Microbiome in CKD Progression and Therapy.Journal of clinical medicine · 2026Review
- Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors.Clinical and experimental nephrology · 2026Article
- Iron Profile Variability in Hemodialysis Chronic Kidney Disease Patients.Journal of clinical laboratory analysis · 2025Article
- Iron in Vascular Calcification: Pro-Calcific Agent or Protective Modulator?International journal of molecular sciences · 2025Review
- Kidney involvement and anemia in COVID-19 infection.World journal of nephrology · 2025Review
- Comparison of administration of oral versus Infusions intravenous iron therapy in diabetic patients with chronic kidney disease receiving Erythropoietin.Pakistan journal of medical sciences · 2025Article
- The Efficacy and Safety of a Personalized Protocol Designed to Balance Hemoglobin Levels in Hemodialysis Patients as Led by Nephrology Clinical Nurse Specialists: An Intervention Study.Healthcare (Basel, Switzerland) · 2025Article
- Assessment of Serum Phosphate Levels in Chronic Kidney Disease Patients Across Different Stages of Kidney Disease.Cureus · 2025Article
- Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD.Kidney international reports · 2025Article
- A whole-body mechanistic physiologically-based pharmacokinetic modeling of intravenous iron.Drug delivery and translational research · 2025Article
- Intravenous iron treatment fuels chronic kidney disease-induced arterial media calcification in rats.The Journal of pathology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Iron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia. Oral and intravenous iron agents are both available to replete iron in patients with chronic kidney disease diagnosed with iron deficiency. The choice of which agent to use is most often dictated by goals of therapy, tolerability, convenience, and response to prior therapy. Diminished absorption of iron in the gastrointestinal tract and a high incidence of gastrointestinal adverse effects can reduce the efficacy of oral iron agents, necessitating the use of i.v. iron formulations to treat iron deficiency anemia, particularly in patients requiring kidney replacement therapy. Newer oral agents may help to overcome these limitations and help treat iron deficiency in those not requiring kidney replacement therapy. Recent studies have provided new evidence that more aggressive repletion of iron in patients with chronic kidney disease requiring kidney replacement therapy may provide benefits with respect to anemia management and hard clinical outcomes such as cardiovascular disease and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.